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Abstract
Among the adult population, renal cell carcinoma (RCC) constitutes the most prevalent form of
kidney neoplasm. Unfortunately, RCC is relatively asymptomatic and there are no tumor markers
available for diagnostic, prognostic or predictive purposes. Molecular profiling, the global analysis
of gene and protein expression profiles, is an emerging promising tool for new biomarker
identification in RCC. In this review, we summarize the existing knowledge on RCC regarding
clinical presentation, treatment options, and tumor marker status. We present a general overview
of the more commonly used approaches for molecular profiling at the genomic, transcriptomic and
proteomic levels. We also highlight the emerging role of molecular profiling as not only
revolutionizing the process of new tumor marker discovery, but also for providing a better
understanding of the pathogenesis of RCC that will pave the way towards new targeted therapy
discovery. Furthermore, we discuss the spectrum of clinical applications of molecular profiling in
RCC in the current literature. Finally, we highlight some of the potential challenging that faces the
era of molecular profiling and its transition into clinical practice, and provide an insight about the
future perspectives of molecular profiling in RCC.
Renal cell carcinoma: A clinical overview
The American Cancer Society predicts that there will be
about 54,000 new cases of kidney cancer in the United
States in 2008, and about 13,010 people will die from this
disease http://www.cancer.org. Among the adult popula-
tion, renal cell carcinoma (RCC) constitutes the most
prevalent form of kidney neoplasia, and can be patholog-
ically classified into subtypes: the clear cell type, which
constitutes 80% of all cases, the papillary type, at around
15%, and the remaining 5% of other histological types.
Certain subtypes, like chromophobe RCC, have a better
prognosis compared to ccRCC. Other types, like collecting
duct, medullary and sarcomatoid types have a more
aggressive course. Early stage RCC is relatively asympto-
matic, and the classical triad of flank pain, hematuria, and
a renal mass only manifests very late in the course of the
disease. The diagnoses of RCC is confirmed with imaging
studies such as CT and ultrasound, and many cases of
RCC are now accidentally discovered during routine
imaging [1]. Kidney biopsy is an invasive technique that
might result in complications and will not be able to pro-
vide accurate diagnosis in certain situations.
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While surgery may be curative for localized disease, many
patients eventually relapse. The 5-year survival rate for
metastatic RCC is ≤ 10% [2,3]. The greatest risk of recur-
rence following resection of RCC is within the first 3–5
years [4]. Detecting recurrences early is important and can
impact patient outcome since the likelihood of a favora-
ble response to systemic treatment is greater when the
metastatic burden is limited [5] and surgical resection of a
single or limited number of metastases can result in long-
term survival [6]. The anatomic extent of disease is the
most consistent factor that determines prognosis in
patients with resected RCC [7]. The UCLA Integrated Stag-
ing System (UISS) incorporates histologic grade and the
ECOG performance status and has further improved on
the prognostic information contained using the TNM sys-
tem [8,9]. The most commonly used prognostic model for
patients with metastatic disease is based on a multivariate
analysis from the Memorial Sloan Kettering Cancer Centre
[10].
While surgery is the treatment of choice for localized dis-
ease, treatment of advanced RCC is more challenging.
Prior to the availability of targeted therapies, Interferon-α
(INF) was the standard of care but was associated with a
low response rate and significant toxicity [11,12]. High
dose interleukin-2 (IL-2) has a similar response rate as
IFN, but can cure approximately 3–5% of patients
[13,14]. With targeted antiangiogenic drugs, we have
entered a new era in the therapy of patients with advanced
RCC [15,16]. In previously untreated patients Sutent
improves overall survival when compared to INF [17]
while Nexavar improves progression free survival (PFS)
2nd line after immunotherapy when compared to best sup-
portive care. Temsirolimus, an mTOR inhibitor, has been
shown to improve overall survival vs. INF in previously
untreated patients with high-risk RCC [18]. More recently
the combination of Avastin and Interferon has been
found to improve PFS when compared to Interferon alone
in previously untreated patients [19,20] and Everolimus
(RAD001), an orally administered inhibitor of mTOR,
improves PFS in patients 2nd line after progression on
Sutent, Nexavar, or both compared to best supportive care
[21]. Multiple other targeted drugs are in clinical trials.
The current status of tumor markers in RCC
A tumor marker can be defined as a surrogate indicator
that increases or decreases the clinician's suspicion to can-
cer susceptibility, onset, progression, or recurrence and
whether a specific treatment will decrease the risk of such
events [22]. There are currently no established tumor
markers for RCC in clinical practice; tumor size and stage
offer the only viable tools to predict prognosis [23]. More
recently, a number of new molecular markers have been
investigated, and although many show clinical potential,
none has gained approved clinical application [24]. Lack
of B7H1 and B7H4 expression is a strong predictor of
overall survival in patients without metastases [25-28].
Another potentially important marker is IMP3[29,30].
While data from clinical trials provide general guidelines
for the best 1st and 2nd line therapies for metastatic RCC,
these are not always the best choices for each individual
patient. There are very few biomarkers that can guide cli-
nicians in the choice of therapy for each individual
patient. In patients with clear cell RCC, responses to IL-2
were associated with the presence of alveolar features in
more than 50 percent of the sample, and an absence of
papillary features or granular features [31]. Carbonic
anhydrase IX (CAIX) expression is HIF dependent and its
expression is increased in VHL mutated RCC. High levels
of CAIX expression are associated with a more favorable
prognosis and a greater likelihood of a response to IL-2
[32,33]. There are no biomarkers available to predicting
responsiveness to molecularly targeted agents. Measure-
ments of VEGF and the soluble VEGF receptor do change
in response to treatment but whether such alterations can
be used, as a surrogate for tumor responsiveness remains
unknown.
Molecular profiling
Molecular Profiling (MP) can be defined as the classifica-
tion of biological specimens, like tissues, blood or urine,
based on multiple molecule (like gene, protein, miRNA)
expression patterns or genomic changes for diagnostic,
prognostic, and predictive purposes [34]. The 1990s ush-
ered in an era of information churning out faster than its
analysis. The completion of the Human Genome Project,
rapid advances in bioinformatics, the application of new
technologies like mass spectroscopy and array analysis –
that allow simultaneous high throughput analysis of
thousands of molecules – and emergence of new treat-
ment options like targeted therapy, necessitated the birth
of global analysis to allow for a more complete under-
standing of the malignant process. MP creates a paradigm
shift from the traditional approach of looking at one mol-
ecule a time to the simultaneous high-throughput analysis
of thousands of molecules. The focus starts to switch into
a more "global" analysis of dysregulated genes and pro-
teins, and other molecules, in order to obtain a better
understanding of the potential "cross-talks" between
them. This has substantial clinical impact in the field of
clinical oncology, as described below in more details with
specific reference to RCC.
Molecular profiling approaches
Molecular profiling is a multifaceted process which can be
explored on three different levels: genomic, transcrip-
tomic and proteomic. Each takes a different angle on the
global picture. Table 1 summarizes the different common
tools for molecular profiling. Among the tools men-Molecular Cancer 2009, 8:20 http://www.molecular-cancer.com/content/8/1/20
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tioned, the most widespread are microarray technology
and mass spectrometry.
Microarray analysis
Since its introduction in the mid-1990s [35], microarray
analysis has become an established technique to simulta-
neously compare gene expression patterns between differ-
ent conditions. Generally speaking, a microarray is a
compact chip containing a large number of well-defined
immobilized capture molecules (synthetic oligos, mRNA
transcripts, proteins, antibodies etc), that are capable of
assaying molecules through hybridization with a labelled
probe [36]. It has been used to analyze gene expression
profiles in many malignancies through exploration of the
alterations that account for the transition from a benign,
to a dysplastic, to an invasive cancer, and of alterations
leading to the development of metastasis. Microarrays
have been of great value in the discovery of biomarkers for
the field of diagnostic pathology, which have been dis-
cussed elsewhere [37]. As shown in table 1, a microarray
can compare different entities among themselves,
whether genomic, transcriptomic, or proteomic. mRNA
microarray is the most popular approach. Databases of
gene expression profiles in various malignancies are now
publicly available [38]. More recently, the technology
extended to include microRNA microarrays, DNA arrays
(comparative genomic hybridization; CGH), protein
arrays, and tissue microarrays. There are several platforms
for microarray analysis, including planar, immobilized
bead, liquid bead, and barcode nanoparticles or quantum
dots.
Advantages of microarray technology include the mini-
mal amount of tissue and reactants needed to generate
feasible results and the high degree of sensitivity. It can be
also automated and can produce quantitative data.
Although microarray is continually being improved,
many drawbacks need to be addressed before bringing the
technology to the bedside, including the lack of standard-
ization, reproducibility, variability of the results due to
specimen type and preparation, and the need to develop
a quality control for the procedure. Added to this is the
microarray's inability to reveal post-transcriptional gene
control [39]. More details about microarray are reviewed
elsewhere [40].
Mass spectrometry
Further insight into the molecular mechanisms of cancer
can also be gleaned through proteome analysis. Proteom-
ics offer considerable advantages over its genomic coun-
terpart since protein is the ultimate agent responsible for
the malignant phenotype. Proteomics can also identify
Table 1: Different tools for molecular profiling at the genomic, transcriptomic, and protein levels
Genomic
• Comparative Genomic Hybridization (CGH)
￿ Array-based CGH
￿ Single Nucleotide Pleomorphism (SNP)
￿ Multi-colour FISH
￿ high-throughput sequencing techniques (hybridization-based, cycle-based, and single molecule based)
￿ High-throughput analysis of methylation.
￿ Spectral karyotyping (SKY)
Transcriptomic
￿ Microarray
￿ mRNA
￿ microRNA
￿ Serial Analysis of Gene Expression (SAGE)
￿ Expressed Sequence Tags (EST)
￿ Digital Differential Display (DDD)
￿ Single Nucleotide Pleomorphism (SNP)
￿ Quantitative RT-PCR
￿ High throughout sequencing
￿ In-situ hybridization
Proteomic
￿ Mass spectrometry (different versions)
￿ Protein microarray
￿ Tissue microarray
￿ ChromatographyMolecular Cancer 2009, 8:20 http://www.molecular-cancer.com/content/8/1/20
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alterations in post-translational modifications and cellu-
lar trafficking that may not be detected by RNA-based
expression studies. Mass spectrometry (MS) has proven to
be an invaluable tool for the characterization of protein
structure and their amino-acid sequences. MS promises to
unveil the complex molecular events characterizing tum-
origenesis and help in the study dynamic protein expres-
sion, post-translational modifications, cellular and sub-
cellular protein distribution, and protein-protein interac-
tions, which has already culminated in the identification
of many cancer-related biomarkers and potential new
drug targets [41].
Several techniques have been used for protein profiling.
Two-dimensional (2-D) gel electrophoresis coupled with
MS was the traditional strategy and, to date, has yielded
several potentially relevant cancer biomarkers [42]. Other
methods include solid-phase extraction followed by
matrix-assisted laser desorption/ionization mass spec-
trometry (MALDI MS) as well as selective surface binding
and surface-enhanced laser desorption/ionization (SELDI
MS) [43]. More recently, another approach has been
developed in which proteins from two samples to be com-
pared are tagged with differing isotopic composition. The
two samples are then combined and processed in a single
batch thereby allowing relative quantification to be per-
formed. An effective labeling strategy uses isotope-coded
affinity tag (ICAT) [44], or, in the most recent variation,
uses isobaric tagging reagent, iTRAQ [45], followed by
multidimensional LC and MS/MS analysis which allows
simultaneous quantification. Recent guidelines from the
National Academy of Clinical Biochemistry highlighted
the need for standardization and quality control before
MS can be involved in clinical care [46]. Detailed discus-
sion about MS is beyond the scope of this review.
Traditionally, the goal of most proteomic studies is to
identify biomarkers that can be measured by enzyme-
linked immunosorbent assay (ELISA). Improvements in
proteomic technology may be changing this because there
are now efforts to develop proteomic technologies directly
into clinical diagnostic tests. An example of this technol-
ogy is surface-enhanced laser desorption ionization time-
of-flight (SELDI-TOF) MS. This technology, combined
with pattern recognition based on bioinformatics tools,
and discriminatory spectrum proteomic profiles can be
generated to help discriminate individuals with cancer
from those with benign disease.
Other techniques
Comparative Genomic Hybridization (CGH) is a method
that allows for the comparison of genomic alterations as
DNA sequence copy variations, insertions, and deletions,
between two types of tissues. Chromosomal changes in
cancer can be scanned using CGH whereby the test (can-
cer) and control (normal), are labeled and hybridized
with normal metaphase chromosomes. Competition for
hybridization with the metaphase chromosomes arises
between test and control DNA and fluorescent techniques
are then used to assess DNA gain or loss in cancer [47]. A
more recent advance in the technique utilizes a microar-
ray format that allows much better resolution in detecting
chromosomal aberrations.
Another technique assays genomic changes using Single
Nucleotide Polymorphism (SNP), which are variations in
a given DNA base between different members of the same
species. Found at frequencies of one every 1000–2000
base pairs, much of human genetic diversity is attributed
to SNP variation between individuals. This gives SNP
analysis a potentially useful diagnostic application for
haplotype-related disease, and recent work has begun tak-
ing advantage of this [48].
Recent evidence suggests that microRNAs, small non-cod-
ing oligonucleotides that regulate gene expression, are
dysregulated in various malignancies, and have promising
clinical roles as cancer biomarkers. miRNA microarrays
have shown the ability to accurately classify cancers and to
be potential prognostic and predictive markers for many
tumors [49].
Clinical utility of molecular profiling
The suite of clinical applications of molecular profiling in
cancer is broad, encompassing a wide variety of fields.
Constituting some of these clinical applications are diag-
nosis, prognosis, prediction of treatment efficiency,
patient follow-up after surgery for early detection of recur-
rence, and the sub-grouping of patients into smaller cate-
gories, thus allowing for individualization of treatment
options. One of the revolutionary aspects of MP is chang-
ing our traditional paradigm in classifying cancer. Patho-
logical classification can shift from the histological scale –
that often gives little information on prognosis, individu-
alized treatment options, and chance of recurrence, over-
looking the fact that many patients with similar
histological types might experience markedly different
disease courses – to the molecular scale, which offers a
highly detailed, global perspective on the disease process,
promising superior performance over traditional classifi-
cations.
Moreover, MP is a key for better understanding of cancer
initiation and progression. MP, which can also lead to the
development of new targeted therapy options – especially
ones designed against the inherently intractable meta-
static stages of cancer – that can complement existing
treatment options. Simultaneous analysis of multiple
markers identified by MP can lead to much improvement
in sensitivity and specificity. Another interesting applica-Molecular Cancer 2009, 8:20 http://www.molecular-cancer.com/content/8/1/20
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tion is the ability of a MP signature to distinguish benign
from malignant tumors, which is not always feasible via
histological analysis alone. Tumors of unknown origin are
another common challenge in histopathology practice,
and the use of MP signatures to identify the tissue of ori-
gin in these poorly differentiated tumors, where morphol-
ogy cannot help, will have a great impact on patient care.
Molecular profiling in RCC
A more detailed look at how MP can affect our under-
standing and management of RCC will now be discussed.
Molecular profiling of RCC has been performed at differ-
ent levels, including RNA, protein, genomic and more
recently miRNA. As is the case in other tumors, there are
several potential clinical applications of MP in RCC.
The first application is investigating the presence of a "sig-
nature expression profile" in RCC that would allow a dis-
tinction to be made between it and normal tissue. A
number of studies have analyzed differential gene expres-
sions in RCC at the mRNA level [50-54]. Lenburg et al.
[55] highlighted the poor overlap among many of these
studies and underscored the need for accurate statistical
methods to be applied to microarray analysis and also to
filter out defective samples and genes that are not reliably
detected. Liou et al [56] demonstrated a significant differ-
ence between data obtained from tissues vs. cell lines.
When Laser microdisected tissues of RCC were used for
microarray analysis, the top dysregulated genes identified
were significantly different from bulk tissues [57], suggest-
ing that a more "pure" malignant population can lead to
more accurate results. Dalgin et al recently identified a
number of hypermethylated genes in RCC using methyla-
tion assays coupled with computational screening [58].
There are a few reports on protein profiling of RCC [59-
63] that have identified a number of potential biomarkers
[64,65]. Urinary proteomics, and more recently metabo-
lomics, are emerging new fields for biomarker discovery
in urinary tract diseases [66]. In kidney cancer, a recent
pilot study analyzed urine samples from RCC and con-
trols [67], where metabolic profiling and pathway analy-
ses were significantly different. Another study investigated
the clinical utility of SELDI profiling of urine samples in
conjunction with neural-network analysis to detect renal
cancer and to identify proteins of potential use as prog-
nostic markers, but the results were not reproducible [68].
Identifying proteomic markers directly from the serum of
RCC patients is more challenging. Attempts of serum pro-
filing of RCC patients by SELDI-TOF [69,70] were not
reproducible when validated in an independent popula-
tion [71].
Very recently, miRNA research has emerged with great
clinical potential in RCC. Potential usefulness of miRNA
profiling in RCC include its potential ability to determine
the tissue of origin (through a kidney-specific signature)
in tumors of unknown primary [72]. A recent study iden-
tified four miRNAs that were significantly up regulated in
kidney cancer [73]. More recently, a total of 33 differen-
tially expressed miRNAs were identified in clear cell RCC,
including 21 up-regulated miRNAs (our data, submitted
for publications). Bioinformatics and literature searches
showed that many of these have been reported to be dys-
regulated in other malignancies and have a potential role
in cancer pathogenesis. Interestingly, the differentially
expressed miRNAs showed a significant correlation with
reported regions of chromosomal aberration sites that
included regions of amplification or loss. Preliminary
analyses showed that some of these targets can be directly
involved in RCC pathogenesis (our manuscript, submit-
ted for publication).
A second interesting potential role for MP is distinguish-
ing the different types of renal tumors. A good example of
this is the differentiation between oncocytoma and
chromophobe RCC – two different forms of kidney
tumors notoriously confused for one another because of
their microscopic similarity. Indeed, both cancers were
found by microarray to constitute a high degree of similar-
ity in mitochondrial gene expression. Further gene analy-
ses, however, showed differences in gene expression
profiles between the two conditions [74]. Another study
used mRNA expression profiles to properly distinguish
between clear cell carcinoma and chromophobe carcino-
mas [75]. A third report showed the reliability of MP in
accurately classifying different subtypes of RCC [76].
Approximately 5% of clear cell renal cell carcinomas con-
tain a sarcomatoid component. The nature of this compo-
nent is not well understood. Studies, however, have begun
shedding light on this topic through MP. Comparing
allelic loss patterns in clear cell and sarcomatoid compo-
nents of RCC, Jones et al [77] suggested that both compo-
nents are derived from the same progenitor cell. Different
patterns of allelic loss were observed in clear cell and sar-
comatoid components from the same patient, indicating
genetic divergence during the clonal evolution of RCC.
Moreover, retrospective analysis has shown superior per-
formance of MP in detecting mixed subtypes and cases
with confusing histological patterns. Another report iden-
tified groups of genes that can distinguish the clear cell
and chormophobe types of RCC [78]. Higgins et al. [79]
used DNA microarrays to classify, on a molecular scale,
papillary carcinomas from conventional RCC and cancers
from different parts of the kidney.
Monzon et al [80] recently showed that SNP arrays can
detect characteristic chromosomal aberrations in paraffin-
embedded renal tumors, and thus offer a high-resolution,Molecular Cancer 2009, 8:20 http://www.molecular-cancer.com/content/8/1/20
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genome-wide method that can be used as an ancillary
study for classification and potentially for prognostic
stratification of these tumors. Using microarray analysis,
gene signatures were identified that distinguish RCC from
other cancers with 100% accuracy. Differentially
expressed genes during early tumor formation and tumor
progression to metastatic RCC were also found. Moreover,
a previously described "global" metastatic signature was
validated in RCC. [81]. Another study identified a set of
80 genes that was sufficient to classify tumors with a very
low error rate. Distinct gene expression signatures were
associated with chromosomal abnormalities of tumor
cells, metastasis formation, and patient survival. [82].
Such studies underscore the practical usefulness of MP in
determining the nature and subtype of the patient's ill-
ness.
Molecular profiling has important prognostic applica-
tions in RCC. The use of microarrays identified numerous
prognostic biomarkers. Such markers can help stratify
patients into prognostic risk groups and guide future ther-
apy decisions. A recent microarray analysis identified two
major subgroups within RCC, based on gene expression
profiling, that differ in biological behaviour despite simi-
larity in histology [83]. Another microarray-based analy-
sis has shown that approximately 40 genes can accurately
make the distinction between patients with a relatively
non-aggressive form of the disease compared to patients
with aggressive disease [84]. These molecular signatures
were shown to supersede conventional staging in predict-
ing outcome. Moch et al [85] identified 89 differentially
expressed genes in RCC. One of these, vimentin, is a
marker of poor prognosis.
In addition to expression profiling, cytogenetic changes
might also have prognostic value in RCC. A recent report
showed that loss of chromosome 9p was found to be an
independent indicator of poor prognosis in RCC [86].
Boer et al found that gene expression signature can distin-
guish early from advanced metastatic stage (Stage IV)
tumors [87].
Using tissue microarray analysis, Kim et al [88] con-
structed a combined molecular and clinical prognostic
model for survival that was significantly more accurate
than standard clinical parameters. The recent identifica-
tion and potential incorporation of molecular markers
into current staging systems of renal cell carcinoma is
expected to revolutionize the staging of the tumor [89].
Two prognostic nomogram models to predict survival
after nephrectomy were created. One was based exclu-
sively on molecular markers and the other on a combina-
tion of clinical variables and molecular markers [90].
Findings suggest that the integration of molecular profil-
ing with clinical parameters could enhance diagnosis and
prognosis of the disease.
A forth important application of MP in RCC is identifying
predictive markers. It can be used to predict response to
immunotherapy and targeted therapy [91]. Profiling anal-
ysis can be very helpful in identifying targets for immuno-
therapy and targeted molecular therapy [92]. The fifth and
critical objective of MP is elucidating the pathogenesis of
RCC. Accumulation of hundreds of dysregulated genes
identified by different studies elicited the next step of
"understanding" the interaction between these molecules.
An early report, using Gene Ontology analysis, identified
a number of up and down regulated biological processes,
some overlapping with other malignancies and others are
unique for RCC [93]. Similar findings were observed by
Gieseg et al [94], who identified enrichment of certain
biological processes like cellular adhesion, matrix integ-
rity, and signal transduction mechanisms. Liou et al found
that genes involved in cell adhesion where dominantly
upregulated while those involved in transport were down
regulated [95].
More recently, pathway analyses have emerged. Extensive
pathway analysis allowed the discovery of significant
pathways in clear cell RCC, including glycolysis, pro-
panoate metabolism, pyruvate metabolism, the urea
cycle, and arginine/proline metabolism, as well as in the
non-metabolic p53 and FAS pathways [96]. Knowledge of
networks, processes, and pathways altered in kidney can-
cer may be used to influence the choice of therapy. More
recently, we identified a number of pathways that are sig-
nificantly enriched in RCC. While some of these are "com-
monly" dysregulated pathways in many cancers, like cell
cycle, apoptosis, cell adhesion and MAP kinase pathways,
other interesting pathways, not previously linked to RCC
were also ientified, including insulin signaling, PPAR sig-
naling, hemostasis and blood coagulation, pyruvate
metabolism and TCA cycle (our manuscript, submitted
for publication) are also involved. Interestingly, although
there was only a minimal overlap between published pro-
tein lists, there was significant overlap between the identi-
fied pathways between groups. Preliminary analysis also
shows the presence of interaction networks among dys-
regulated proteins [96].
More recent efforts are focused on integrated analysis of
different levels of molecular changes to allow better
understanding of the pathogenesis of RCC. A recent report
performed an integrated analysis of DNA and RNA pro-
files of RCC samples. Combining genomic and transcrip-
tomic data, they identified 71 differentially expressed
genes in aberrant chromosomal regions and observed, in
amplified regions, a predominance of up-regulated genes
and a trend to clustering [97].
Cytogenetic analysis has also been an invaluable tool to
insight into the pathogenesis of RCC. Earlier studies
showed that chromosomal aberration are involved in theMolecular Cancer 2009, 8:20 http://www.molecular-cancer.com/content/8/1/20
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development of RCC, and that they can guide our under-
standing of the molecular events needed for development
and progression of RCC [98,99]. A study showed that
array-based CGH is capable of distinguishing the vast
majority of renal cell carcinomas from normal and benign
lesions based on their genetic profiles of DNA copy
number variations [100]. Yoshimoto et al., also using
array CGH, found that chromosomal alterations in clear
cell RCC are significantly different from those of chromo-
phobe RCC, and that up and down-regulated genes signif-
icantly localize within areas of chromosomal gain or loss,
respectively [101].
Challenges of molecular profiling
The transition of molecular profiling from the research
bench into a clinical setting necessitates addressing several
challenges. One of these is how to integrate several
modalities to achieve a multi-dimensional molecular pro-
file of the patient's specimen. This requires a collaborative
effort between many elements of the health care team,
particularly clinicians, research scientists, computer
experts, and statisticians. A team approach is necessary for
the transition of various parameters into a clinically
meaningful format that will help in obtaining a compre-
hensive picture of each individual tumor and aid in diag-
nosis, assist in prognosis, and in individualizing the line
of treatment. Accumulation of data from various research
laboratories and meta analysis studies will definitely help
to reach a more solid understanding of how to transfer MP
into a clinical setting. Full transparency in reporting
results (especially the negative ones) should be empha-
sized to avoid selection bias for positive results reporting.
Challenges facing the use of MP in clinical decision mak-
ing have been addressed in details in a number of recent
excellent reviews [102]. A major limitation of most pub-
lished reports is the heterogeneity of the analyzed mate-
rial, from tissues to cell lines to biological fluids, and
combining different histological types, stages and grades.
An important issue is the need for standardization of MP
testing. Standardization encompasses several aspects
including the specimen type (fresh frozen versus formalin
fixed paraffin embedded tissues), the appropriate method
of specimen storage, the platform to be used, the experi-
mental conditions, and the clinical interpretation of the
test results. Another important issue is the choice of the
targets (which and how many genes or proteins to be
included).
Tissue preservation and handling is a prime issue to be
considered. Formalin-fixed tissue used for histopatho-
logic diagnosis cannot be used for MP. Sacrificing a por-
tion of the diagnostic tissue for molecular analysis might
compromise the quality of the pathological diagnosis.
Ongoing solutions for this problem include the use of
non-formalin alcohol based fixatives which preserve RNA
quality.
Heterogeneity of the tumor tissue is another important
factor to be considered in this regard. Tumor tissue repre-
sents a mixture of tumor, adjacent normal, and stromal
elements. There are different approaches that have been
taken to deal with this problem, including a cultured cell
line, global survey, and micro-dissection profiling [103].
A new molecular profiling analysis test must be able to
provide additional information for diagnostic, prognos-
tic, or predictive purposes that are beyond classical fac-
tors. Unfortunately, due to lack of prospective studies, the
performance of many molecular profiling experiments are
not additionally significant than classical markers. More-
over, at the discovery phase, many of the experiments lack
statistical significance since they are not initially designed
with enough power to address the hypothesis. Added to
this is the lack of well-defined clinically annotated cases
and specimens. Results must therefore be validated, pref-
erably by an independent data set. Cross-validation
within the same set is a weakness that hinders generaliza-
tion of the results.
A recent report by the National Academy of Clinical Bio-
chemistry Laboratory Medicine Practice Guidelines [104]
expounded upon two main technologies commonly
implemented in MP, microarray and mass spectrometry,
and developed recommendations on what must be done
before for their application in the clinical realm.
Cost is another challenge. This includes running costs and
the need to buy new expensive equipments for molecular
testing. However, the cost of the commonly used tech-
niques, such as microarrays, continues to decrease as it
becomes more widespread. In addition, focusing on fewer
targets will be an important factor in reducing costs. Ethi-
cal and legal issues are expected to represent an additional
challenge especially in cases of hereditary or familial
tumors.
Molecular profiling: A glimpse at the future
Before the era of molecular profiling, cancer diagnosis,
prognosis, and subsequent treatment decisions were
based on histopathologic parameters, usually the tissue of
origin and the stage and grade of the tumor. Years of expe-
rience have shown morphological classification to be defi-
cient in many aspects and that patients with the same
histopathologic picture can have unexplained variable
outcomes. Individual molecular markers have been
slowly added to ameliorate the accuracy of predicting
prognosis and prediction of treatment efficiency. Exam-
ples of this are the immunohistochemical assessment of
the estrogen and progesterone receptors in breast cancerMolecular Cancer 2009, 8:20 http://www.molecular-cancer.com/content/8/1/20
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and pre-operative prostate specific antigen (PSA) meas-
urement.
Entering into the era of molecular profiling, many scien-
tists were excited and felt that MP would be able to revo-
lutionize our clinical practice and replace most traditional
tools [105]. After a period of initial enthusiasm, scientists
and clinicians began to realize the major obstacles that
face the clinical utilization of MP. Molecular profiling is
not likely to replace anatomical pathology, and a more
stance is that it will slowly be added in conjunction with
the classical diagnostic and prognostic parameters.
Development of clinically meaningful application of
molecular profiling can be roughly divided into three
stages [106]. The first stage, nearly accomplished, is the
identification of all the "players" that share in the patho-
genesis of cancer. With completion of the human genome
project and the major advances in gene prediction pro-
grams, many new genes, splice variants, and non-coding
molecules, have been identified. This sets the stage for the
next phase of comparing molecular profiling in normal
vs. cancer and at different stages of cancer. Data is now pil-
ing about differential gene and protein expression in renal
cell carcinoma. Cytogenetic and microRNA changes are
also accumulating.
An emerging important, and more difficult, third stage is
the incorporation of these multiple parameters into one
picture. The ongoing efforts of protein-protein interac-
tions analysis and pathway analysis represent two impor-
tant steps on the right track towards an understanding of
the meaning of these pathological changes, and conse-
quently applying them for diagnostic and treatment
efforts. At this phase, bioinformatics will play a chief role.
The integral task of bioinformatics encompasses a wide
variety of areas including the availability of cancer data-
bases and providing sophisticated analytical tools that are
capable of analyzing an enormous amount of data.
MP can also provide a "multi-parametric" approach in
cancer biomarkers, where a combination of multiple
markers will lead to enhanced sensitivity and specificity,
as compared to individual markers. More recently, we
have witnessed the emergence of commercial molecular
profiling-based analytical tests that are used to answer
specific questions related to certain subgroups of patients.
One commercially available kit is used to assess the
chance of recurrence in certain subgroups of breast cancer
patients. Another kit is utilizes gene expression profiling
to identify the tissue of origin in cancers of unknown pri-
mary. Finally, the molecular profiling approaches should
be customized for different cancers. The questions to be
addressed and the clinical utility depend on prevalence,
natural history, and the available treatment tools for each
individual cancer.
Figure 1 shows one possible future scenario where molec-
ular analysis is performed hand in hand with usual his-
topathologic evaluation, allowing for a more
individualized picture that constitutes more details about
every individual cancer, including the aggressiveness and
treatment options. This tumor "fingerprint" will help
avoiding extra costs and side effects associated with the
unnecessary use of certain lines of treatment in patient
who will not benefit from them.
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